The Lancet Commission on Skin Health: A Global Plan to Reduce the Burden of Skin Disease, Expand the Dermatology Workforce and Integrate New Technologies

Key Highlights:
Introduction
Why The Lancet Commission Matters for Global Health
Who Is Leading the Commission and What They Bring
The Four Case Studies: Rationale and Expected Insights
Workforce Shortages: Magnitude, Consequences and Pathways to Scale
Integrating Skin Health into Primary Care and Universal Health Coverage
Technology, AI and Diagnostics: Promise and Prudence
Measuring Success: What Measurable Targets Should Look Like
Policy and Financing: How Governments and Donors Can Act
Implementation Science and Research Gaps
Real-World Examples That Inform Scalable Solutions
Ethical and Equity Considerations
What to Expect from the Commission Over the Next 2–5 Years
Risks and Barriers to Impact
Pathways for Clinicians, Policymakers and Civil Society to Act Now
The Commission’s Potential to Reframe Global Health Priorities
FAQ

Key Highlights:

The Lancet has launched its first-ever Commission dedicated to skin health, aiming to set measurable global targets and delivery models to reduce the burden of skin disease and strengthen the workforce.
The Commission will focus on four case studies — industrialization-driven disease shifts (China), global workforce shortages, neglected tropical diseases (Nepal), and melanoma with AI-assisted diagnostics (Australia) — to inform policy and practice.
The effort is backed by the International League of Dermatological Societies (ILDS) and co-chaired by Xiang Chen, Esther E. Freeman, and Sinéad Langan; it seeks integration of skin health into primary care, universal health coverage and scalable training for front-line providers.

Introduction

Skin disease affects billions of people worldwide, shaping quality of life, social participation and economic productivity. Despite its prevalence and clear public-health consequences — pain, itch, stigma, disability and, in some cases, shortened life expectancy — dermatology has not consistently commanded high-level international attention. That dynamic shifts with The Lancet’s decision to establish its first Commission devoted solely to skin health. Endorsed by the International League of Dermatological Societies (ILDS), the Commission brings convening power, epidemiological rigor and a mandate to produce concrete, measurable targets and delivery models that health systems can adopt.

The Commission’s work will span research synthesis, policy design and pragmatic solutions for scarce-workforce settings, and will highlight where technology can responsibly assist diagnosis and care. By focusing on four illustrative case studies — each selected to surface distinct challenges and solutions — the initiative intends to show how global principles can translate into locally relevant actions. The next two to five years promise a major reframing: skin health will be treated as an integral component of universal health coverage rather than an optional specialty niche.

Why The Lancet Commission Matters for Global Health

A Lancet Commission carries influence. Historically, commissions published by The Lancet set agendas that affected international policy priorities and funding. Previous commissions on obesity and global surgery reshaped clinical definitions, resource allocation and national target-setting. The decision to convene experts on skin health signals that dermatologic conditions are being reclassified from cosmetic afterthoughts to serious public-health priorities.

The World Health Assembly’s 2025 resolution recognizing “Skin Disease as a Global Public Health Priority” created a policy opening. That resolution followed decades of advocacy and coalition-building; the Commission aims to translate high-level recognition into operational targets, workforce development strategies and delivery models that ministries of health, donor agencies and professional bodies can adopt.

Several concrete shifts make this moment opportune. Noncommunicable inflammatory skin diseases — including eczema, psoriasis and chronic urticaria — are rising in many regions undergoing urbanization and lifestyle change. Simultaneously, endemic infectious skin diseases and neglected tropical diseases remain dominant burdens in parts of sub-Saharan Africa, South Asia and other low-resource settings. Skin cancers continue to climb in high-income countries with aging populations and histories of high ultraviolet exposure. A single global strategy will need differentiated, context-sensitive responses; the Commission’s case-study approach is designed to produce those.

Who Is Leading the Commission and What They Bring

The Commission is co-chaired by three internationally recognized figures in dermatology and epidemiology:

Xiang Chen, MD, PhD — professor of dermatology at Xiangya Hospital in China, who brings clinical and population-level experience in a country navigating rapid industrialization.
Esther E. Freeman, MD, PhD, FAAD — director of global health dermatology at Massachusetts General Hospital and associate professor at Harvard Medical School, who directs global dermatology workforce and integration efforts and will lead the workforce case study.
Sinéad Langan, professor of clinical epidemiology at the London School of Hygiene & Tropical Medicine and honorary consultant dermatologist at St John’s Institute of Dermatology, who contributes epidemiological expertise.

Henry W. Lim, MD, president of the ILDS, emphasized that the Commission positions dermatology on the global health stage, supported by “one of the world’s most influential scientific voices.” The ILDS represents more than 175,000 dermatologists worldwide and served as a key coalition partner in building momentum for the World Health Assembly resolution.

The Commission will draw other experts across clinical dermatology, public health, health systems research, implementation science, health workforce planning and digital health. Multidisciplinary membership will be essential: sustainable solutions must link clinical standards to training curricula, supply chains for essential medicines, information systems and financing mechanisms.

The Four Case Studies: Rationale and Expected Insights

The Commission uses focused case studies to go deep where a single report cannot cover every dermatologic condition and context. Each case study is intended to illuminate broader principles.

Industrialization and the epidemiologic transition (China)
Industrialization shifts disease patterns. In regions that historically bore high burdens of infectious skin disease, urbanization and changing lifestyles drive increases in inflammatory, noncommunicable skin disorders such as atopic dermatitis, contact dermatitis and acne. China serves as a model for how large-scale demographic and environmental change alters dermatologic needs across urban and rural populations. The Commission will analyze surveillance data, environmental exposures, access disparities and health system responses to propose scalable prevention and primary-care strategies.
Global dermatology workforce (global focus; led by Esther Freeman)
Workforce shortages constrain care. Some countries have only a few dermatologists for entire populations — the Commission cites Rwanda (about 14 dermatologists for the country, most in the capital), Burundi (six dermatologists for roughly 14 million people) and Malawi (four dermatologists). These stark figures require new models: training primary care and front-line providers to manage the most common conditions, strengthening referral pathways, and using telemedicine and community-based strategies. The Commission will identify priority skills and curricula (e.g., training in the top 10 most common skin conditions), describe task-shifting models and propose measurable targets for workforce expansion and upskilling.
Neglected tropical diseases with skin manifestations (Nepal focus)
Neglected tropical diseases (NTDs) disproportionately affect the world’s poorest populations. Approximately 80% of NTDs involve a major skin manifestation. The Commission will examine how integrated skin-health strategies can amplify progress on NTD control and elimination — for example, by improving case detection through trained community health workers, simplifying diagnostic pathways and coordinating mass drug administration with basic dermatologic care.
Melanoma and skin cancer diagnostics with AI (Australia focus)
AI and decentralized diagnostic tools are most advanced for skin cancer detection. Australia, which has long battled high melanoma incidence, provides a laboratory for assessing the benefits, pitfalls and privacy considerations of AI-assisted diagnostics. The Commission will evaluate clinical effectiveness, equity (who gains access to AI tools), data governance and patient privacy, and how AI can complement, not replace, clinical judgment.

Taken together, these case studies span a wide spectrum — from infectious disease control in low-resource settings to advanced technology applications in high-income systems. Findings will illuminate the tensions between specialized dermatologic care and scalable primary-care integration.

Workforce Shortages: Magnitude, Consequences and Pathways to Scale

The global shortage of dermatologists is central to the problem. The Commission’s workforce case study will quantify shortages and trace downstream effects: delayed diagnosis, inappropriate or suboptimal treatment, recourse to unregulated remedies, and greater morbidity and social stigma.

Consequences of scarcity

Delayed diagnosis of skin cancers and advanced presentations.
Uncontrolled inflammatory disease leading to years of pain, sleep disturbance and disability.
High out-of-pocket expenditure where patients seek private specialists or unregulated treatments.
Overburdened primary care clinicians who lack dermatology training and may mismanage conditions.
Weak referral networks and limited access in rural and peri-urban communities.

Pathways to expand capacity

Prioritize training for the top 10 most prevalent and burdensome skin conditions. The Commission recommends focusing training resources on conditions that account for the bulk of morbidity, rather than attempting to cover all 2,000–3,000 dermatologic diagnoses.
Task-shifting and task-sharing. Community health workers, primary-care clinicians and nurses can be trained to recognize, manage and triage common skin conditions, and to recognize red flags that require specialist referral. Curriculum modules, practical case-based training and supervised clinical exposure improve diagnostic accuracy and management.
Extend specialist reach with teledermatology. Store-and-forward teledermatology and real-time teleconsultations allow dermatologists to advise on cases in remote areas. Programs in various countries have reduced referral wait times and improved diagnostic concordance. The Commission will examine evidence on cost-effectiveness and scalability.
Mentorship and hub-and-spoke models. Centers of excellence can mentor regional clinicians through regular tele-education, case review and short-term visiting attachments. The Project ECHO model — where specialists mentor primary-care teams through videoconferencing — has been adapted to dermatology in some settings and offers a scalable continuing-education pathway.
Integrate dermatology into pre-service and in-service curricula. Medical schools and nursing programs should include practical dermatology modules; continuous professional development platforms can update clinicians on evolving therapeutic options and resistance patterns.
Strengthen supply chains and access to essential medicines. Training alone will underperform if basic medications and laboratory services are unavailable. The Commission will address procurement, formulary inclusion and financing pathways.

A pragmatic workforce strategy will set measurable milestones: numbers trained, percentage of primary care providers with core dermatology competencies, time-to-specialist opinion benchmarks via telemedicine and reductions in untreated prevalence for targeted conditions.

Integrating Skin Health into Primary Care and Universal Health Coverage

Medical systems that separate dermatology from primary care perpetuate access gaps. Integration requires three elements: clinician capacity, appropriate referral pathways and financing models that reduce catastrophic costs.

Clinician capacity Primary care clinicians can be trained to diagnose and manage common conditions, treat uncomplicated bacterial or fungal infections, recognize drug reactions and manage inflammatory diseases at mild-to-moderate severity. Algorithms and simple diagnostic tools — supported by clinical decision support in electronic medical records or mobile applications — increase diagnostic accuracy and standardize care. Training should be competency-based and locally adapted.

Referral pathways Clear triage criteria determine which patients need specialist evaluation, which can be managed by primary care, and when community-based interventions are appropriate. Teletriage systems let dermatologists advise remotely, maintain oversight and educate the referring clinicians simultaneously.

Financing and service delivery models Including basic dermatologic services within universal health coverage benefits packages ensures that care is affordable. Policies that reimburse teleconsultations, remunerate training initiatives and fund essential dermatologic medicines reduce financial barriers. Health-system planners should consider community-based screening programs for high-burden conditions, integrated with other primary-care services like maternal and child health visits.

Community engagement and stigma reduction Many skin diseases cause visible lesions that trigger stigma and social exclusion. Public health campaigns should combine accurate information about causes and treatments with outreach to communities to reduce discrimination. Community health workers and peer-support groups play a role in adherence and early care-seeking.

Technology, AI and Diagnostics: Promise and Prudence

Digital technologies will be part of the Commission’s findings, especially in the melanoma case study. Diagnostics for skin disease range from simple clinical photography to AI-enabled image classification. The potential benefits are considerable: improved access to specialist-level review, faster triage of lesions suspicious for cancer, and augmentation of clinical decision-making in primary care.

Evidence and limitations AI models trained on large, diverse image datasets have demonstrated promising diagnostic accuracy in controlled settings, particularly for pigmented lesions and melanoma. However, performance varies across skin phototypes, lesion subtypes and imaging conditions. Models developed primarily on images of lighter skin can underperform in darker skin, raising equity concerns. Data governance, patient privacy, and informed consent are central — decentralized learning approaches (such as federated learning) are being explored to preserve privacy while pooling model improvements.

Operational issues

Quality of images. Clinical utility depends on consistent, adequately lit, focused photographs. Simple point-and-shoot devices and smartphone attachments can improve image quality.
Workflow integration. AI outputs need to be integrated into clinical workflows so that recommendations are actionable and do not generate burden.
Regulatory oversight. Devices and algorithms should meet regulatory standards and be validated prospectively in diverse populations before large-scale deployment.
Complementarity. AI should augment clinician expertise, not replace it. Systems that flag concerning lesions for expedited specialist review strike a balance between efficiency and safety.

Examples and early adopters Australia’s experience with teledermatology and AI pilot projects informs the Commission’s approach. In other settings, telemedicine has connected remote clinicians to specialists and reduced time to diagnosis. The Commission will evaluate real-world implementation studies to identify best practices, model safeguards and recommend pathways for equitable deployment.

Measuring Success: What Measurable Targets Should Look Like

To be useful for policymakers, Commission recommendations must translate into actionable metrics. The Commission aims to define measurable targets and timelines akin to the UN Sustainable Development Goals, adapted for skin health and health-system realities.

Potential target areas

Burden reduction: Percent reduction in years lived with disability (YLDs) attributable to skin disease for target conditions within a defined timeline.
Access: Proportion of the population with access to a primary-care provider trained in core dermatology competencies within a specified distance or travel time.
Workforce: Increase in the number of trained primary-care clinicians with dermatology competencies and expansion of dermatologists per region where feasible. Instead of prescribing a single global dermatologist-per-population ratio, targets can be regional and incremental, reflecting resource constraints.
Timeliness: Median time from first presentation to specialist opinion or definitive treatment for priority conditions such as suspected melanoma or severe drug reactions.
Coverage: Inclusion of key dermatologic interventions and medicines in essential benefits packages and national formularies.
Equity: Reduction in disparities in access and outcomes across rural/urban, socioeconomic and skin phototype groups.
Diagnostic quality: Proportion of referrals completed with adequate clinical information and images for teledermatology review; sensitivity and specificity benchmarks for AI-assisted diagnostic tools validated across skin types.

Operationalizing metrics The Commission will recommend data collection frameworks that blend routine health information systems, sentinel surveillance, facility-based audits and population surveys. Standardized indicators and minimal datasets enable cross-country comparisons and progress tracking over time.

Policy and Financing: How Governments and Donors Can Act

Policy levers and financing mechanisms shape how quickly Commission recommendations become practice.

National policy actions

Adopt national skin-health strategies that embed skin conditions within broader noncommunicable disease frameworks and primary-care strengthening agendas.
Integrate dermatology modules into medical and nursing curricula and mandate continuing professional development in dermatologic competencies for primary-care providers.
Define referral and telehealth reimbursement policies and include teledermatology in digital health strategies.
Ensure essential dermatologic medicines and diagnostic supplies are listed on national essential medicines lists and procured through reliable supply chains.

Donor and global health community roles

Support implementation research and capacity-building in low- and middle-income countries (LMICs) to test scalable models for workforce training and teledermatology.
Fund technology pilots that prioritize equitable validation across skin phototypes and include robust data governance frameworks.
Align NTD control programs with skin-health priorities, leveraging shared surveillance and community outreach infrastructure.

Metrics-driven financing Performance-based financing and results-based aid can target measurable outcomes (e.g., increased numbers of primary-care providers trained, reduced prevalence of untreated scabies or fungal infections in sentinel communities). Financing models must be carefully designed to avoid perverse incentives and to sustain gains after project funding ends.

Implementation Science and Research Gaps

The Commission will identify evidence gaps and propose an agenda for implementation science: which interventions work, for whom, under what conditions, and at what cost. Key research priorities include:

Comparative effectiveness of training modalities for primary-care clinicians (short courses, longitudinal mentorship, e-learning).
Cost-effectiveness and equity impacts of teledermatology versus decentralized specialist deployment.
Prospective validation of AI diagnostic tools across diverse populations and clinical environments.
Integration of skin-health indicators into routine health information systems and sentinel surveillance.
Operational models for integrating NTD control with routine dermatologic services.

Filling these research gaps will require partnerships among academic institutions, ministries of health, professional societies and funders. Implementation studies should incorporate mixed methods: quantitative outcomes, qualitative assessments of acceptability and assessments of health-system readiness.

Real-World Examples That Inform Scalable Solutions

Several existing initiatives provide practical lessons:

Teledermatology programs in resource-limited settings have shortened referral times and improved diagnostic concordance when coupled with training for image capture and structured referral templates.
Task-shifting programs that equip nurses or community health workers with clinical algorithms for common skin conditions have improved early detection and reduced inappropriate antibiotic use.
Integrated NTD campaigns that include skin examinations during mass drug administration reach marginalized populations and can identify comorbid skin conditions for treatment or referral.
Decentralized AI trials using federated learning approaches demonstrate that models can be improved across distributed datasets without centralized data pooling, preserving privacy while improving diagnostic performance.

These examples illustrate a central principle: context-specific combinations of training, technology and system redesign produce sustained improvements.

Ethical and Equity Considerations

Scaling dermatology services globally raises ethical questions. Priorities must include:

Equity in data and model development. AI tools require diverse datasets to avoid bias across skin phototypes and socio-demographic groups.
Informed consent and data privacy, particularly for clinical images and AI model development. Federated learning and local data stewardship can mitigate risks.
Protecting against commercialization that prioritizes profitable markets over neglected populations. Public-interest safeguards should govern partnerships with industry.
Cultural competence. Interventions must respect local beliefs and practices concerning skin disease and healing.

Ethics must be embedded in implementation guidelines, training materials and monitoring frameworks.

What to Expect from the Commission Over the Next 2–5 Years

The Commission will produce a major report — described by The Lancet as a “launch” — after synthesizing evidence, stakeholder input and case-study insights. Historically, Lancet Commissions take two to five years to produce comprehensive reports that outline evidence, specific targets and policy recommendations. Along the way, working groups may publish interim analyses, policy briefs and implementation toolkits aimed at ministries, professional societies and donor agencies.

Stakeholders should anticipate actionable outcomes, including:

A set of measurable global targets and recommended indicators for skin health.
Practical workforce development strategies and curricula for primary-care and front-line clinicians.
Policy guidance on integrating skin health into universal health coverage and national health packages.
Recommendations on ethical deployment and validation of AI and telehealth for dermatology.
Country-level roadmaps or adaptable models informed by the four case studies.

The Commission’s success will depend on broad stakeholder engagement, including ministries of health, professional societies, patient groups and technology partners.

Risks and Barriers to Impact

Several obstacles could limit the Commission’s influence if not addressed:

Political attention and funding may be limited relative to competing priorities, particularly where skin disease is perceived as low priority.
Implementation gaps between high-level recommendations and ground-level capacity will require sustained investment.
Technology deployment without appropriate validation and governance risks entrenching inequities.
Workforce expansion requires time; immediate gains will hinge on training existing primary-care cadres and leveraging remote support.

Mitigating these barriers demands strategic advocacy, realistic timelines, phased implementation and evidence-based pilots that demonstrate early wins.

Pathways for Clinicians, Policymakers and Civil Society to Act Now

While the Commission completes its work, several practical steps can accelerate progress:

For clinicians and professional societies

Advocate for inclusion of dermatology modules in medical and nursing curricula.
Establish mentorship and teleconsultation networks linking specialists with primary-care teams.
Promote workplace-based training and continuous professional development opportunities in dermatology.

For policymakers and health planners

Review national benefits packages to include essential dermatologic medicines and basic diagnostic services.
Pilot teledermatology and task-shifting programs with rigorous evaluation components.
Integrate skin-health indicators into routine health data systems.

For civil society and patient groups

Raise awareness about the burden and treatability of common skin conditions.
Partner with health services to reduce stigma and promote early care-seeking.
Advocate for funding priorities that address gaps in access to care.

Collective action across these groups will create momentum and demonstrate feasibility for larger investments.

The Commission’s Potential to Reframe Global Health Priorities

Elevating skin health through a Lancet Commission has ripple effects. It reframes dermatology from a specialty silo to a cross-cutting domain that intersects with NTD control, primary-care strengthening, cancer control and digital health policy. By establishing measurable targets and practical delivery models, the Commission can influence donor agendas, national planning and clinical training — and, crucially, reduce the suffering of millions who live with treatable dermatoses.

The challenge will be to translate recommendations into sustained change: funding pipelines, political will and local implementation pathways will determine whether the Commission’s work reshapes health systems. Nonetheless, the Commission has created an institutional focal point and timeline for action. It will give ministries, professional societies and funders a shared blueprint for improving skin health at scale.

FAQ

Q: What is a Lancet Commission and why is this important?
A: A Lancet Commission gathers multidisciplinary experts to synthesize evidence, set targets and propose policy and practice recommendations on a major health issue. This Commission is the first in the journal’s history devoted solely to skin health, signaling a shift in global recognition and offering a coordinated blueprint for change.

Q: Who is leading the Commission and which organizations support it?
A: The Commission is co-chaired by Xiang Chen (Xiangya Hospital), Esther E. Freeman (Massachusetts General Hospital and Harvard Medical School) and Sinéad Langan (London School of Hygiene & Tropical Medicine). The International League of Dermatological Societies (ILDS) supports and helped catalyze the initiative.

Q: What are the Commission’s primary goals?
A: The Commission aims to raise the profile of skin disease as a major public-health issue, set measurable targets, propose delivery models for care (especially where dermatologists are scarce), and provide policy guidance on workforce development, integration into primary care, and responsible use of technology.

Q: Why use case studies, and which countries are being examined?
A: Case studies allow the Commission to investigate diverse settings deeply and produce actionable recommendations. Initial case studies focus on China (industrialization and epidemiologic transition), the global dermatology workforce (with examples from countries like Rwanda, Burundi and Malawi), Nepal (neglected tropical diseases with skin manifestations) and Australia (melanoma and AI diagnostics).

Q: How long will the Commission’s work take?
A: Lancet Commissions typically take two to five years to synthesize evidence and produce comprehensive reports. The Lancet describes the “launch” as the beginning of a process that sets targets and timelines for the coming decade.

Q: How will the Commission’s findings be implemented?
A: Findings will be disseminated through The Lancet and stakeholder briefings. Implementation will require ministries of health, professional societies, donors and civil society to adopt and adapt recommendations, fund pilot projects and scale proven interventions such as training initiatives, teledermatology programs and validated AI tools.

Q: What immediate measures can countries take before the Commission report is published?
A: Countries can begin by integrating basic dermatology training into primary-care curricula, piloting teledermatology networks, ensuring access to essential dermatologic medicines, and aligning NTD programs with broader skin-health strategies. These steps create readiness for larger-scale reforms.

Q: What role will technology and AI play?
A: Technology offers diagnostic support, remote specialist access and educational platforms. AI has shown promise for skin cancer detection but requires careful validation across diverse skin types, robust privacy protections and integration into clinical workflows. The Commission will recommend safeguards and best practices.

Q: How will equity and ethical issues be addressed?
A: The Commission will prioritize equity by emphasizing diverse data for AI development, protecting patient privacy, ensuring culturally competent care and preventing market-driven deployment that leaves marginalized populations behind.

Q: How can clinicians and researchers contribute to the Commission’s work?
A: Clinicians and researchers can participate in working groups, contribute data and pilot studies, advocate for national strategies, and engage in capacity-building partnerships.

Q: Where can I find more information or contact Commission members?
A: Esther Freeman, one of the co-chairs, is publicly available via professional channels. The ILDS can provide updates on Commission activities and how professional societies can engage.

Q: Will the Commission address all skin diseases?
A: The Commission will not cover every dermatologic condition in depth. Instead, it uses case studies and priority conditions to produce focused, implementable recommendations that address the most burdensome and actionable areas.

Q: How will success be measured?
A: Success will be measured by agreed-upon indicators such as reductions in morbidity (YLDs) for targeted conditions, increased access to trained primary-care providers, improved referral and diagnostic timeliness, inclusion of dermatologic services in health benefits packages and reductions in equity gaps.

Q: What is the anticipated timeline for policy impact?
A: Impact timelines will vary. Some interventions, like training primary-care clinicians and piloting teledermatology, can yield measurable improvements within one to three years. System-level changes, workforce expansion and national policy adoption typically take longer and require sustained investment.

Q: Will private-sector partners be involved, especially in AI development?
A: Partnerships with industry are likely, but the Commission will emphasize public-interest safeguards, equitable access and robust validation to prevent unintended harms or inequities.

Q: How will the Commission engage low- and middle-income countries?
A: The Commission includes case studies focused on LMIC contexts and intends to work with local stakeholders, ministries of health, professional societies and community organizations to ensure recommendations are relevant and implementable.

Q: How can patients and civil society participate?
A: Patients and civil society can contribute by sharing lived experiences, advocating for access to care, participating in awareness campaigns to reduce stigma and collaborating on community-based interventions.

Q: What immediate benefits can patients expect from this initiative?
A: Immediate benefits will depend on how quickly national and local actors adopt the Commission’s interim recommendations. In the near term, expect increased attention to skin health, pilot programs that expand teleconsultation and training, and stronger advocacy for inclusion of dermatologic services in health packages.

Q: Where will the Commission publish its final report?
A: The final Commission report will be published in The Lancet and disseminated through partner organizations, policymaker briefings and professional networks.